OverviewSuggest Edit

Teligent is a specialty generic pharmaceutical company which develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products. The Company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The Company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services.

TypePublic
Founded1977
HQVineland, US
Websiteteligent.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Dec 2018)189(+4%)
Job Openings3
Revenue (FY, 2019)$156.3 M(-1%)
Share Price (Sept 2020)$0.8 (-23%)
Cybersecurity ratingAMore

Key People/Management at Teligent

Tim Sawyer

Tim Sawyer

President & CEO
Damian Finio

Damian Finio

CFO
Antonio di Nicola

Antonio di Nicola

General Manager and Vice President of Operations
Eric Muse

Eric Muse

Vice President, BD
Show more

Teligent Office Locations

Teligent has offices in Vineland, Woodbridge Township, Mississauga and Tallinn
Vineland, US (HQ)
105 Lincoln Ave
Woodbridge Township, US
33 S Wood Ave #730, Iselin
Mississauga, CA
5995 Avebury Rd #804
Tallinn, EE
Akadeemia tee 21/5
Show all (4)

Teligent Financials and Metrics

Teligent Revenue

Embed Graph
View revenue for all periods
Teligent's revenue was reported to be $156.30 m in FY, 2019
USD

Revenue (Q2, 2020)

36.7m

Gross profit (Q2, 2020)

25.6m

Gross profit margin (Q2, 2020), %

69.8%

Net income (Q2, 2020)

(14.3m)

EBIT (Q2, 2020)

(4.4m)

Market capitalization (23-Sept-2020)

4.5m

Closing stock price (23-Sept-2020)

0.8

Cash (30-Jun-2020)

5.9m

EV

23.6m
Teligent's current market capitalization is $4.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

7.8m8.6m18.2m33.7m44.3m66.9m67.3m158.3m156.3m

Cost of goods sold

5.5m5.8m12.1m16.9m22.9m32.2m39.9m43.5m42.4m

Gross profit

2.3m2.8m6.1m16.8m21.3m34.7m27.4m114.8m113.9m

Gross profit Margin, %

29%32%34%50%48%52%41%73%73%
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Teligent Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Teligent Online and Social Media Presence

Embed Graph

Teligent News and Updates

Teligent Announces Completion of Series D Convertible Note Exchange

BUENA, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 million aggregate principal amount of Zero Coupon Convertible Senio…

Teligent, Inc. Announces Second Quarter 2020 Results

BUENA, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2020.

Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020

BUENA, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19th, 2020 to discuss the 2nd quarter 2020 financial results and business update.

Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announce that John Celentano, a current independent director of Teligent, has been appointed Chairman of Teligent's…

Teligent, Inc. Announces Hiring of Chief Legal Officer and Corporate Secretary

BUENA, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16, 2…

Teligent, Inc. Announces First Quarter 2020 Results

BUENA, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020.
Show more

Teligent Frequently Asked Questions

  • When was Teligent founded?

    Teligent was founded in 1977.

  • Who are Teligent key executives?

    Teligent's key executives are Tim Sawyer, Damian Finio and Antonio di Nicola.

  • How many employees does Teligent have?

    Teligent has 189 employees.

  • What is Teligent revenue?

    Latest Teligent annual revenue is $156.3 m.

  • What is Teligent revenue per employee?

    Latest Teligent revenue per employee is $827 k.

  • Who are Teligent competitors?

    Competitors of Teligent include Sirona Biochem, Genome & Company and Farmalider.

  • Where is Teligent headquarters?

    Teligent headquarters is located at 105 Lincoln Ave, Vineland.

  • Where are Teligent offices?

    Teligent has offices in Vineland, Woodbridge Township, Mississauga and Tallinn.

  • How many offices does Teligent have?

    Teligent has 4 offices.